Publications and Presentations. (a) Corvus may publish or present the final results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity to review and provide comments in accordance with subsection (b).
(b) In the event that either Party (for purposes of this Section, the “Publishing Party”) wishes to publish or present any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentations) at least [***] days (or [***], in the case of abstracts) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (i) delete from such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation to delete any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such Party’s development activities outside of the Study.
(c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data shall be determined in accordance with appropriate scientific and academic standards and customs.
Publications and Presentations. For purposes of this Agreement, “Scientific Publication” means any scientific publication or medical communication regarding Study results in any form that is intended for disclosure to third parties, including, without limitation, manuscripts, abstracts, posters, slides or other materials used for presentations.
Publications and Presentations. The Parties acknowledge that scientific lead-time is a key element of the value of the research and development activities under the Collaboration and further agree that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or disclosure of results of the research or development activities hereunder. At least thirty (30) days prior to submission of any material related to the research or development activities hereunder for publication or presentation, the submitting Party will provide to the receiving Party a draft of such material for its review and comment. The receiving Party will provide any comments to the submitting Party within twenty (20) days of receipt of such materials alerting the submitting Party to the presence of the receiving Party’s Confidential Information or patentable subject matter that requires protection and in each case, specifically identifying such information (“Notice of Objection”). Each Party will reasonably review proposed publications and presentations submitted by the other Party as promptly as possible and will not unreasonably withhold its consent to such publications or presentations that have been submitted for review with less than the required notice period.
5.3.1 In the event the receiving party makes such Notice of Objection, the submitting party shall refrain from disclosing the material until the receiving Party’s Confidential Information, as identified in the Notice of Objection, is removed. Once the receiving Party’s Confidential Information has been removed, the Notice of Objection will be deemed withdrawn and the submitting party shall not be restricted from publishing the material, provided that any objection based on patentable subject matter contained in the material has also been addressed in accordance with the terms of section 5.3.2.
5.3.2 If the Notice of Objection identifies patentable subject matter then the submitting Party will withhold the material from submission for publication or presentation and the Parties shall work together in good faith and, as quickly as possible after receipt of the Notice of Objection, to file patents and take all necessary measures to establish and preserve proprietary rights that may be contained in the material being submitted for publication or presentation as identified in the Notice of Objection. Once the Parties have taken such steps to protect the patentable subject matter, the Notice of Obje...
Publications and Presentations. Please list the journal article publications based on the findings of this work. Please indicate their status (planned, in draft, under review, submitted, in-press, published). Please indicate the conferences to which you have submitted abstracts and their status (i.e. accepted, oral presentation / poster presentation) Please list any invitations for oral presentations where you have or plan to present the findings of this research.
Publications and Presentations. Without Pfizer's written prior approval, Supplier shall not:
a) make any presentation, public announcement, or publication of any kind relating to any and all matters arising out of or in connection with this PO, including this PO itself, or
b) use in any matter whatsoever any trademarks, logos, service marks, trade names, corporate names, proprietary logos, indicia or other business identifiers of any sort of Pfizer.
Publications and Presentations. 4.1 Each Party will have the right to publish or give public presentations of the Common Results (as defined in § 5.1) but shall be subject to the prior written agreement of all of the other Parties. The details and timing of the decision to publish or give a presentation and the extent and content of the publication or presentation shall also be agreed beforehand, in writing between all the Parties (see §§ 4.3 and 4.4). Any other publication or presentation of the Common Results is strictly forbidden to the Parties. For the avoidance of doubt, unless otherwise agreed in writing by the concerned Parties, no publication or presentation of any Party’s Background IP and/or Own Common Results is permitted, directly as indirectly, in any manner whatsoever.
4.2 All publications and presentations on the Common Results shall be made under the joint authorship of the Parties in compliance with the rules of good scientific practice. Furthermore, all publications and presentations shall include that the Research Project, and more generally, this Agreement, is covered by a grant from the Xxxxx Xxxxxxxxxx- Xxxxx COFUND Programme “InnovaXN” (contract number 847439 with the European Commission). Each submission for publication shall be signed by the Supervisors referred to in § 2.5. Each presentation shall contain written text that acknowledges and mentions the joint authorship and the contribution made by each of the Parties in compliance with the rules of good scientific practice. For the sole need of the present article 4.2, each Party consents to the others, in the terms and conditions hereunder convened, a free and non-exclusive right of exploitation of its name and logo, for the validity period of this Agreement. This right shall cease immediately and automatically in case of termination of this Agreement, whatever the cause or the date. Prior termination against a/several Party(ies) shall however not call into question the survival of this right for the non- concerned Parties, which remains in force, until the agreed contractual term.
4.3 The Party wishing to publish shall notify the other Parties by submitting a copy of the manuscript for review and comment, so as to arrive at least 45 (forty five) calendar days before the due date for submission for publication. The Party wishing to give a presentation shall notify the other Parties by submitting for review and comment a copy of the description of the content of the presentation and a copy of any visual aids to ...
Publications and Presentations. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to be published or presented, the results of or information pertaining to the Research Program or any Development Plan for, or Co-Development of, a Fully-Exercised Co-Developed Product, without the prior review by and approval of an authorized representative of the other Party. Further, ARCHEMIX shall not publish or present, or allow to be published or presented any information pertaining to (a) Development of a Product that is not a Fully-Exercised Co-Developed Product or (b) any Commercialization activities, without the prior review by and approval of an authorized Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. representative of ELAN. Except with respect to Fully-Exercised Co-Developed Products, ELAN shall be free to publish and present results of Development, including details regarding the relevant Lead Compounds, Clinical Candidates and/or Products, in accordance with the remainder of this Section 6.3. The Parties acknowledge that scientific publications and public presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Accordingly, each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or public presentations (including, without limitation, information to be presented verbally to the public) that relate to the Research Program or any Co-Development Program at least [***] days prior to its intended public presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [***] day period, not to submit such abstract or manuscript for publication or to make such public presentation until the other Party is given up to [***] days from the date of such written request to seek appropriate patent protection for any material in such intended publication or public presentation that it reasonably believes may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by each Party, the same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submi...
Publications and Presentations. The publication and presentation of Study Data and Sample Data, including provisions regarding the Confidential Information of a Party contained in such a disclosure, is governed by Section 8.2.
Publications and Presentations. Sponsor acknowledges that Rice and the Project Team members shall have the right to publish or otherwise publicly disclose at academic and professional conferences and other meetings the results of the Engineering Design Project, subject to the following limitations. A draft copy of the proposed publication or public presentation (except for student theses and dissertations) shall be provided to Sponsor for its review at least 30 days prior to submission for publication or public presentation. During such 30 day period, Sponsor may request that Rice delay the proposed publication or public presentation for up to an additional 30 days to allow for patent or copyright filings or other matters related to the protection of Intellectual Property. In addition, Sponsor may suggest changes to the proposed publication or public presentation, but the author shall retain final authority; provided, however, that the author shall be obligated to remove any Confidential Information furnished by Sponsor pursuant to Section 6 below. Notwithstanding anything in this Agreement to the contrary, copyrights in publications, public presentations and other scholarly writings shall be owned by their respective authors.
Publications and Presentations. Proposals for specific analyses made by the DAC Working Groups will have a limited period of protected time (9-12 months) from the time of Program Data receipt, in which similar proposals from other investigators are rejected. If after this period no results have been shared with the SC by the DAC Working Group, a collaboration might be proposed between the DAC Working Group and the other investigators with a similar proposal. • In the title of the Publications or Presentations it must be made clear that the Program is sponsored by BIG. • Prior to submission to the journal/conference of a proposed Publication or Presentation, the first author shall share the final draft with the SC coordinator at BIG Headquarters (HQ) (xxxxxx.xxxxx@xxxxxxxxxxxx.xxx) for review by the SC. • The SC shall review and approve the material to be published or presented within ten (10) working days for a Publication and five (5) working days for a Presentation.
